Who are mOPV type 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): mOPV2 at 6 and 7 weeks of age, mOPV2 at 6 and 8 weeks of age, RotaTeq™ (V260), Live Attenuated H1N1 Influenza Vaccine, Rotarix (RV1), Live Smallpox Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mopv-type-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

mOPV type 2 — Competitive Intelligence Brief

mOPV type 2 (mOPV type 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

marketed Live attenuated vaccine Poliovirus type 2 Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

mOPV type 2 (mOPV type 2) — University of Chile. mOPV type 2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 through mucosal and systemic immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
mOPV type 2 TARGET	mOPV type 2	University of Chile	marketed	Live attenuated vaccine	Poliovirus type 2
mOPV2 at 6 and 7 weeks of age	mOPV2 at 6 and 7 weeks of age	Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Poliovirus type 2
mOPV2 at 6 and 8 weeks of age	mOPV2 at 6 and 8 weeks of age	Centers for Disease Control and Prevention	marketed	Live attenuated vaccine	Poliovirus type 2
RotaTeq™ (V260)	RotaTeq™ (V260)	Merck Sharp & Dohme LLC	marketed	Live attenuated vaccine
Live Attenuated H1N1 Influenza Vaccine	Live Attenuated H1N1 Influenza Vaccine	University of Rochester	marketed	Live attenuated vaccine
Rotarix (RV1)	Rotarix (RV1)	Telethon Kids Institute	marketed	Live attenuated vaccine	Rotavirus VP4 and VP7 surface proteins
Live Smallpox Vaccine	Live Smallpox Vaccine	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"	marketed	Live attenuated vaccine	Vaccinia virus antigens (envelope and intracellular proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). mOPV type 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/mopv-type-2. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab